A San Antonio-led randomized clinical trial is giving fresh hope to service members and veterans with stubborn combat-related PTSD. Researchers found that layering an MRI-guided, robot-delivered form of transcranial magnetic stimulation onto intensive psychotherapy produced major symptom relief for most participants. Those who got the image-guided "navigated TMS" plus trauma-focused therapy saw clinically meaningful gains that were still hanging on at one and three months after treatment. Investigators say that if these results hold up in larger studies and survive regulatory scrutiny, the approach could open a crucial new option for people with treatment-resistant combat PTSD.
Trial Results At A Glance
The randomized trial enrolled 119 active-duty and veteran participants. According to JAMA Network Open, 85% of those who received active navigated TMS plus psychotherapy met criteria for clinically significant PTSD symptom reduction at one month, compared with 59% in the sham group. About 73% of the active-treatment group were still improved at three months. The paper lays out the trial design behind those numbers.
What "Navigated TMS" Does
Navigated TMS starts with a patient-specific MRI map, then uses robotically guided coil placement so magnetic pulses are aimed at individualized brain targets instead of a single standard-issue spot. Investigators suggest that this precision helps disrupt maladaptive neural firing patterns tied to trauma responses, which in turn appears to amplify the impact of evidence-based psychotherapies. A summary of the study methods and the mechanism the team reports can be found via MedicalXpress.
Who Was Treated And Where
The study brought 119 service members and veterans into a 30-day residential program at Laurel Ridge Treatment Center in San Antonio. UT Health San Antonio reports that about 92% of participants had severe or extremely severe PTSD when they arrived. The residential setup paired navigated TMS with massed prolonged exposure and cognitive behavioral therapy, described by the investigators as their standard of care for an intensive program. That combination appears to have helped keep dropout rates low during active treatment.
Next Steps Toward Approval And Access
Researchers say the next chapter has to include larger, multisite trials and real-world implementation studies to see whether the results hold outside a residential setting. Dr. Peter Fox told local reporters that the team is in the process of submitting the navigated TMS approach for FDA review, according to reporting by KENS5.
Cautions And Conflicts
The JAMA Network Open article notes that the trial tested navigated TMS only as an add-on to residential psychotherapy, not as a stand-alone treatment, and that follow-up assessment rates dropped after discharge. Both issues limit how much anyone can say about long-term durability. The paper also discloses that the work received funding from Department of Defense sources and that Dr. Fox holds patents related to the navigated TMS method that are licensed commercially, details the authors say readers should keep in mind when interpreting the findings.
What This Means Locally
For San Antonio, often called Military City USA, the trial is being hailed as a homegrown research win that could speed up access to advanced trials and specialty PTSD care for local veterans if future testing and regulatory review go well, according to UT Health San Antonio. Veterans advocates and clinicians are already flagging the fine print, noting that real-world access, cost and the training required for clinicians will determine how fast navigated TMS can move from a tightly run research program into everyday care.
